The article definitely has me thinking about buying some more shares. We’ll be spending lots of dollars battling generics on infringement. Hope we hire a skilled firm, one that knows a cropped table when they see it. If only the FDA would modify the Orange Book to reflect "therapeutic equivalence" coding. That would legitimize "skinny labeling" and protect our share of the market. What are the chances?
A timely Conference Call,including a discussion of the AZN "skinny label" case would be helpful to everyone...including a discussion of "skinny label" cases' effect on innovation.
News 
Market Data 
Discover 
AI
